Finance News
Is it time to start worrying? Analysts have recently lowered their outlook for HOOKIPA Pharma Inc. (NASDAQ:HOOK).
Is it time to be concerned? Analysts have recently lowered their outlook for HOOKIPA Pharma Inc. (NASDAQ:HOOK).,
It appears that things are not looking good for HOOKIPA Pharma Inc. (NASDAQ:HOOK) shareholders, as analysts have significantly revised their forecasts for the company this year. There has been a sharp reduction in revenue estimates, indicating that previous forecasts were overly optimistic.
Following the downgrade, the four analysts covering HOOKIPA Pharma now project revenues of US$27 million in 2024. This would represent a substantial 34% increase in sales compared to the previous 12 months. Losses are expected to decrease significantly by 34% to US$0.55 per share. Prior to this consensus update, analysts were forecasting revenues of US$35 million and losses of US$0.51 per share in 2024. This shift in sentiment is evident, with analysts slashing revenue estimates for this year while simultaneously raising loss per share forecasts.
See our latest analysis for HOOKIPA Pharma
Looking at the bigger picture, one way to interpret these forecasts is to compare them with past performance and industry growth estimates. The latest estimates suggest that HOOKIPA Pharma is expected to experience a significant acceleration in growth, with a forecasted 34% annualized revenue growth through 2024, much higher than its historical growth rate of 7.6% per annum over the past five years. In comparison, other companies in the same industry are projected to grow their revenue at a rate of 17% annually. This indicates that the analysts anticipate HOOKIPA Pharma to outpace industry growth.
The Bottom Line
The key takeaway from this downgrade is the increased forecasted losses for this year, indicating potential challenges for HOOKIPA Pharma. While analysts have lowered revenue estimates, data suggests that revenues are expected to outperform the broader market. Given the significant change in sentiment, it’s reasonable for investors to approach HOOKIPA Pharma with caution.
Following such a downgrade, it is evident that previous forecasts were overly optimistic. Additionally, there are potentially concerning factors in HOOKIPA Pharma’s business, such as significant dilution from new stock issuance in the past year. For more insights, you can click here to discover this and the 3 other risks we’ve identified.
Another way to identify potentially impactful companies is to monitor insider trading activity. Our list of growing companies that insiders are buying provides valuable insights in this regard.
Have questions about this article? Confused about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
FAQ:
Q: What led to the negative revision in HOOKIPA Pharma’s forecasts?
A: The analysts made a substantial negative revision to revenue estimates, indicating a significant change in sentiment and potential challenges for the company.
Q: How do HOOKIPA Pharma’s growth forecasts compare to industry peers?
A: HOOKIPA Pharma is expected to experience accelerated growth, with a forecasted 34% annualized revenue growth through 2024, outpacing the industry average of 17% annual growth.
Q: What are some potential concerns for HOOKIPA Pharma’s business?
A: There are issues such as significant dilution from new stock issuance and increased forecasted losses, suggesting potential challenges for the company.
Q: How can investors stay informed about companies like HOOKIPA Pharma?
A: Monitoring insider trading activity can provide valuable insights into potentially impactful companies. Our list of growing companies that insiders are buying is a useful resource for investors.
‘Shark Tank’ investor Kevin O’Leary joins ‘Fox & Friends’ to discuss Elon Musk and Vivek Ramaswamy leading DOGE, Trump’s potential appointments for Treasury secretary, and the first-ever crypto czar.
Weighing in on rumblings around a potential Trump-appointed crypto czar, popular entrepreneur Kevin O’Leary called on whoever’s nominated to put an end to regulatory indecision.
“We’ve got to stop these shenanigans because this is a technology that affects all 11 sectors of the economy,” O’Leary said Thursday on “Fox & Friends.”
“It provides efficiency and digital payment systems. And we have to be competitive worldwide.”
According to industry sources familiar with the discussions, President-elect Trump is mulling a position dedicated solely to cryptocurrency policy. It’s unclear whether the role would be a czar type or a White House staff role, but the official holding the position would interact with regulators, including the Securities and Exchange Commission and the Commodity Futures Trading Commission.
BITCOIN E.T.F. OPTIONS GO LIVE IN BUSY TRADING. MOST BETS ARE ON GAINS
Two names that come to O’Leary’s mind are former acting U.S. Comptroller of the Currency Brian Brooks and Coinbase CEO Brian Armstrong.
Kevin O’Leary put pressure on a potential Trump-nominated crypto czar to start making regulatory decisions as soon as possible. (Getty Images)
“Brian, of Coinbase, he’s being sued by [SEC Chair Gary] Gensler right now. His company is under litigation from the SEC,” the O’Leary Ventures CEO noted.
“We need a czar here, and we need to start making decisions. Is Ethereum a commodity, or is it a security? Pick one and go with it. I don’t care which one it is, but we’ve got to at least pick it,” he added. “We haven’t done that yet.”
‘Making Money’ host Charles Payne discusses the history of money.
The president-elect campaigned heavily among pro-crypto voters, making a stop at crypto bar PubKey in New York City and speaking at the Bitcoin 2024 conference in Nashville, Tennessee, just weeks before Election Day.
GET FOX BUSINESS ON THE GO BY CLICKING HERE
Manward Press chief investment strategist Shah Gilani discusses how high the S&P 500 can climb in 2025 on ‘Making Money.’
Bitcoin, the largest cryptocurrency by market value, touched a new all-time high of $94,000 in afternoon trading Wednesday and has advanced over 156% from its 52-week low of $36,815.63 in November 2023, as tracked by Dow Jones Market Data Group.
iShares Bitcoin ETF Trust
The surge in price has lifted crypto exchange-traded funds, driving the assets of the largest, iShares Bitcoin Trust, to over $40 billion and lifting it to a record high.
Other bitcoin ETFs are also seeing high interest.
| Ticker | Security | Last | Change | Change % |
|---|---|---|---|---|
| BTC | GRAYSCALE BITCOIN MINI TRT ETF BITCOIN MINI TRUST BTC ETF | 43.34 | +1.50 | +3.59% |
| GBTC | GRAYSCALE BITCOIN TRUST ETF – USD ACC | 77.62 | +2.63 | +3.51% |
| FBTC | FIDELITY WISE ORIGIN BITCOIN FUND – USD ACC | 85.42 | +2.88 | +3.48% |
| ARKB | ARKB – ARK 21SHARES BITCOIN ETF – USD ACC | 97.54 | +3.24 | +3.44% |
FOX Business’ Suzanne O’Halloran contributed to this report.
Product Name: LP – Portmantu
Click here to get LP – Portmantu at discounted price while it’s still available…
All orders are protected by SSL encryption – the highest industry standard for online security from trusted vendors.
LP – Portmantu is backed with a 60 Day No Questions Asked Money Back Guarantee. If within the first 60 days of receipt you are not satisfied with Wake Up Lean™, you can request a refund by sending an email to the address given inside the product and we will immediately refund your entire purchase price, with no questions asked.
Finance News
Ford recalls nearly 25,000 trucks for problem that could make rearview camera malfunction
‘Car Wizard’ David Long joins ‘The Big Money Show’ to share his top ‘no-brainer buys’ under $10,000.
Ford is recalling nearly 25,000 trucks because of a problem that could make the rearview camera system malfunction.
The automaker said water “may enter the Tailgate Park Assist Sensor Interface Module” and lead to a malfunction of the rearview camera image display in 24,950 of its 2023-2024 F-250, F-350 and F-450 trucks.
All the potentially affected trucks feature a tailgate top camera that “provides additional camera images when the tailgate is down and is a separate camera from the primary rear-view camera,” Ford said in a Oct. 25 recall report submitted to the National Highway Traffic Safety Administration (NHTSA).
A 2023 Ford Super Duty F-350 Limited. (Ford Motor Co. / Fox News)
The recall report indicated the problem stemmed from “certain mating interfaces” of the tailgate top camera being “out of tolerance” and the camera bracket “retain[ing] water” during the application.
FORD TO PAUSE PRODUCTION OF F-150 LIGHTNING PICKUP
In the event that the issue occurs, the rearview camera image may show up as “blue or black” or only work “intermittently,” things that could pose a safety issue due to reduced driver visibility, according to the report.
| Ticker | Security | Last | Change | Change % |
|---|---|---|---|---|
| F | FORD MOTOR CO. | 10.24 | -0.04 | -0.39% |
FORD CANCELS PLANS FOR ELECTRIC THREE-ROW SUV
It has not led to any known accidents or injuries, Ford said in another document.
A badge on a vehicle at a Ford dealership in New Lebanon, New York, on Jan. 25. (Angus Mordant/Bloomberg via Getty Images / Getty Images)
According to the recall report, owners of the recalled trucks can get their tailgate top camera, wire harness and TPASIM module swapped out at a Ford or Lincoln dealership for free. Their “Image Processing Module A” will receive a software update too, it said.
“Pick-up and delivery will be available at participating dealerships,” a Ford spokesperson told FOX Business. “We’re also working through other potential options that would make completing this recall as convenient as possible for our customers.”
FORD RECALLS 144,500 MAVERICK TRUCKS DUE TO REARVIEW CAMERA DISPLAY ISSUE
Affected Ford F-250, F-350 and F-40 owners can expect to see a recall notification letter in their mailboxes in early December.
Ford said early last month it has sold over 853,400 of its various types of trucks in the U.S. so far this year.
-
Reverse Mortgage8 months agoHow Reverse Loans Can Provide Financial Relief in Retirement
-
Mortgage Rates8 months agoComo puedo comprar una casa a crédito si no se nada?
-
Reverse Mortgage8 months agoThe Pros and Cons of Using a Reverse Mortgage for Retirement Planning
-
Mortgage Rates8 months agoNiro Loan App 2024 || Niro App Se Loan Kaise Le || New Loan App Best Instant Loan App Without Cibi
-
Reverse Mortgage8 months agoExploring the Myths and Realities of Reverse Mortgages for Seniors in 2024
-
Reverse Mortgage8 months agoUnlocking Your Home’s Value: Everything You Need to Know About HECM Loans
-
USDA Mortgage6 months agoMaking Your Dream of Country Living a Reality: FMHA Rural Home Loans in Focus
-
Reverse Mortgage8 months agoIs a HECM the Right Choice for You? Exploring the Pros and Cons